This finding highlights the potential role of SOCS3 as a molecular mediator of fibrogenesis in MASLD and suggests that its hypomethylation could be an important epigenetic alteration driving disease progression. The gene discussed is SOCS3; the disease is metabolic dysfunction-associated steatotic liver disease.